Anthracite Investment Company Inc. Boosts Stock Position in Grifols, S.A. (NASDAQ:GRFS)

Anthracite Investment Company Inc. grew its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 7.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 659,964 shares of the biotechnology company’s stock after purchasing an additional 45,410 shares during the quarter. Grifols makes up 1.7% of Anthracite Investment Company Inc.’s investment portfolio, making the stock its 11th largest holding. Anthracite Investment Company Inc. owned 0.10% of Grifols worth $4,910,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in GRFS. Whitebox Advisors LLC grew its holdings in Grifols by 56.2% during the third quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock valued at $37,487,000 after purchasing an additional 1,519,093 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Grifols by 144.0% in the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock worth $17,782,000 after acquiring an additional 1,181,959 shares during the period. Brandes Investment Partners LP grew its position in shares of Grifols by 3.0% in the fourth quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company’s stock valued at $152,491,000 after purchasing an additional 592,096 shares in the last quarter. Barclays PLC lifted its holdings in Grifols by 381.2% during the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock worth $5,261,000 after purchasing an additional 469,401 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of Grifols during the third quarter valued at about $2,636,000.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley started coverage on shares of Grifols in a research report on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Trading Down 2.6 %

Shares of GRFS stock opened at $7.55 on Wednesday. The company has a market capitalization of $5.19 billion, a PE ratio of 6.45 and a beta of 0.35. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The business’s fifty day moving average is $7.56 and its 200 day moving average is $8.07. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.